4//SEC Filing
Crowley John F 4
Accession 0000950170-23-071631
CIK 0001178879other
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 5:55 PM ET
Size
7.9 KB
Accession
0000950170-23-071631
Insider Transaction Report
Form 4
Crowley John F
DirectorPresident & CEO
Transactions
- Sale
Common Stock
2023-12-15$12.66/sh−6,043$76,516→ 877,748 total - Award
Common Stock
2023-12-18+34,572→ 912,320 total
Holdings
- 64,895(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.51 to $12.83 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]Represents a contingent right to receive common stock in the amount shown, for no consideration, due to the satisfaction of performance criteria underlying an award of performance based restricted stock units granted in 2021. Such units remain outstanding on the date hereof and will fully vest on December 31, 2023, subject to the Reporting Person's continued service with the Company.
Documents
Issuer
AMICUS THERAPEUTICS, INC.
CIK 0001178879
Entity typeother
Related Parties
1- filerCIK 0001400973
Filing Metadata
- Form type
- 4
- Filed
- Dec 18, 7:00 PM ET
- Accepted
- Dec 19, 5:55 PM ET
- Size
- 7.9 KB